KeyBanc lowered the firm’s price target on Inspire Medical (INSP) to $234 from $236 and keeps an Overweight rating on the shares after the company pre-announced Q4 results for revenue and provided initial 2025 guidance, which the firm viewed as a reasonable starting point. For Q4, Inspire anticipates revenue of $239.5M-$239.7M, which represented a 3% beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $190 from $200 at Stifel
- Inspire Medical Systems Projects Strong Revenue Growth
- Inspire Medical sees FY24 revenue $802.6M-$802.8M, consensus $795.97M
- Inspire Medical sees FY25 revenue $940M-$955M, consensus $950.77M
- Inspire Medical sees Q4 revenue $239.5M-$239.7M, consensus $232.9M